Triveni Bio
A biotech company utilising a genetics-informed precision medicine approach to develop functional antibodies for the treatment of immunological and inflammatory (I&I) disorders.
The company's lead antibody program (TRIV-509) targets kallikreins 5 and 7 (KLK5/7) and directly impacts skin barrier function, inflammation, and itch – providing a meaningful and much needed potential treatment option for patients with atopic dermatitis and other barrier disorders. Triveni hopes to advance TRIV-509 into the clinic in the first half of 2025 and bring second-generation combination approaches into the clinic in 2026.
Latest Triveni Bio News & Features
12 June 2024
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze